RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million At-The-Market Equity Offering Program
August 08 2022 - 3:10PM
(NASDAQ: RXST) – RxSight, Inc., an ophthalmic
medical device company dedicated to improving the vision of
patients following cataract surgery, today announced that it has
filed a $200 million shelf registration statement on Form
S-3 with the Securities and Exchange Commission (the "SEC").
Once declared effective by the SEC, the shelf registration
statement would permit the Company to sell, from time to time, up
to $200 million in aggregate value of its common stock,
preferred stock, debt securities, warrants, and/or units. The shelf
registration statement is intended to provide the Company with
flexibility to access additional capital when market conditions are
appropriate.
As part of the shelf registration, the Company also filed a
prospectus supplement to sell, of the $200 million of securities
being registered, up to an aggregate of $50 million of its common
stock (the "Shares") through an "at-the-market" ("ATM") offering.
The Shares will be offered through BofA Securities as sales
agent.
The registration statement has been filed with the SEC, but has
not yet become effective. These securities may not be sold, nor may
offers to buy be accepted prior to the time that the registration
statement becomes effective.
Prospective investors should read the prospectus, the prospectus
supplement and the other documents that the Company has filed with
the SEC for more complete information about the Company and the ATM
offering, including the risks associated with investing in the
Company. You may get these documents for free by visiting EDGAR on
the SEC website at www.sec.gov. Alternatively, copies of the
prospectus supplement and the accompanying prospectus relating to
the ATM offering may be obtained, when available, from: BofA
Securities, Attention: Prospectus Department, NC1-004-03-43, 200
North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by
email at dg.prospectus_requests@bofa.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company
dedicated to improving the vision of patients following cataract
surgery. The RxSight® Light Adjustable Lens system, comprised of
the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery
Device (LDD™) and accessories, is the first and only commercially
available intraocular lens (IOL) technology that enables doctors to
customize and optimize visual acuity for patients after cataract
surgery. The LAL now features ActivShield™ technology, a
revolutionary UV protection layer built into the lens.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our or our
industry's actual results, levels of activity, performance or
achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied
or inferred by these forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as
"may," "will," "should," "could," "would," "expects," "plans,"
"intends," "anticipates," "believes," "estimates," "predicts,"
"projects," "potential," or "continue" or the negative of such
terms and other same terminology. These statements are only
predictions based on our current expectations and projections about
future events. You should not place undue reliance on these
statements. Actual events or results may differ materially. In
evaluating these statements, you should specifically consider
various factors. These and other factors may cause our actual
results to differ materially from any forward-looking statement. We
undertake no obligation to update any of the forward-looking
statements after the date of this press release to conform those
statements to reflect the occurrence of unanticipated events,
except as required by applicable law.
Company Contact:Shelley B. ThunenChief
Financial Officersthunen@rxsight.com
Investor Relations Contact:ir@rxsight.com
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jun 2024 to Jul 2024
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jul 2023 to Jul 2024